176 related articles for article (PubMed ID: 21062648)
1. What can be concluded from the ERSPC and PLCO trial data?
Studer UE; Collette L
Urol Oncol; 2010; 28(6):668-9. PubMed ID: 21062648
[TBL] [Abstract][Full Text] [Related]
2. PSA-based screening for prostate cancer. Too many adverse effects.
Prescrire Int; 2012 Sep; 21(130):215-7. PubMed ID: 23016259
[TBL] [Abstract][Full Text] [Related]
3. ERSPC and PLCO prostate cancer screening studies: what are the differences?
Schröder FH; Roobol MJ
Eur Urol; 2010 Jul; 58(1):46-52. PubMed ID: 20362385
[No Abstract] [Full Text] [Related]
4. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH
Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
[TBL] [Abstract][Full Text] [Related]
5. Extent of prostate-specific antigen contamination in the Spanish section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Luján M; Páez A; Pascual C; Angulo J; Miravalles E; Berenguer A
Eur Urol; 2006 Dec; 50(6):1234-40; discussion 1239-40. PubMed ID: 16704893
[TBL] [Abstract][Full Text] [Related]
6. [Screening for prostate cancer: results from the first screening round in the French population of the ERSPC trial].
Richard F
Prog Urol; 2009 Jul; 19(7):499-500. PubMed ID: 19559381
[No Abstract] [Full Text] [Related]
7. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK;
J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007
[TBL] [Abstract][Full Text] [Related]
8. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
[TBL] [Abstract][Full Text] [Related]
9. The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer data from a multicenter study (ERSPC).
Roobol MJ; Zappa M; Määttänen L; Ciatto S
Prostate; 2007 Mar; 67(4):439-46. PubMed ID: 17192912
[TBL] [Abstract][Full Text] [Related]
10. PSA and prostate cancer screening: the challenge of the new millennium.
Bjartell A
Eur Urol; 2007 Nov; 52(5):1284-6. PubMed ID: 17720305
[No Abstract] [Full Text] [Related]
11. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker.
Hernández J; Thompson IM
Cancer; 2004 Sep; 101(5):894-904. PubMed ID: 15329895
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
Roobol MJ; Kranse R; de Koning HJ; Schröder FH
Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
[TBL] [Abstract][Full Text] [Related]
13. Screening for prostate cancer (PC)--an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH
Urol Oncol; 2008; 26(5):533-41. PubMed ID: 18774469
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
[TBL] [Abstract][Full Text] [Related]
15. Screening for prostate cancer: reflecting on the quality of evidence from the ERSPC and PLCO studies.
Ilic D
Recent Results Cancer Res; 2014; 202():65-71. PubMed ID: 24531779
[TBL] [Abstract][Full Text] [Related]
16. Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer.
Ellis WJ; Etzioni R; Vessella RL; Hu C; Goodman GE
J Urol; 2001 Jul; 166(1):93-8; discussion 98-9. PubMed ID: 11435831
[TBL] [Abstract][Full Text] [Related]
17. Early diagnosis of prostate cancer: the continuing debate on the impact on mortality.
Höltl W; Lunglmayr G
Wien Klin Wochenschr; 2005 Jul; 117(13-14):440-1. PubMed ID: 16091868
[No Abstract] [Full Text] [Related]
18. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
[TBL] [Abstract][Full Text] [Related]
19. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
Roobol MJ; Roobol DW; Schröder FH
Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.
de Koning HJ; Gulati R; Moss SM; Hugosson J; Pinsky PF; Berg CD; Auvinen A; Andriole GL; Roobol MJ; Crawford ED; Nelen V; Kwiatkowski M; Zappa M; Luján M; Villers A; de Carvalho TM; Feuer EJ; Tsodikov A; Mariotto AB; Heijnsdijk EAM; Etzioni R
Cancer; 2018 Mar; 124(6):1197-1206. PubMed ID: 29211316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
